NEWS
< back to news list

NanoGroup S.A. is launching the next phase of research with a proprietary innovative organ perfusion fluid

After announcing positive results from preliminary studies comparing kidneys perfused with NanOX 10 and NanOX 20 fluids with the current standard used in transplantation, NanoGroup S.A. has begun the next phase of research on the way to marketing its solution. The study, which kicked off on February 6, will take about six weeks.

The goal of the NanoGroup-led OrganFarm project is to implement a new extracorporeal organ storage system to extend the possible shelf life of organs for transplantation. Following a successful study conducted at the Jan Kielanowski Institute of Animal Physiology and Nutrition of the Polish Academy of Sciences by a team led by Prof. dr. hab. med. Maciej Kosieradzki and Dr. hab. n. med. Piotr Domagała of the Department of General and Transplant Surgery at the University Clinical Center of Medical University of Warsaw, NanoGroup S.A. has moved to the next stage of work on its system.

The purpose of the designed study is to reflect one of the situations occurring in transplant practice related to the procurement and storage of an organ for transplantation. The simulation assumes uncontrolled cardiac arrest in a donor in an out-of-hospital setting – the arrival of the emergency medical team in under 30 minutes, undertaking resuscitation with restoration of circulation at a low level, and, once the decision is made to end it, deciding to harvest the organ for transplantation. In such a scenario, the time for organ transplantation is extremely short due to the limitations of being able to store such an organ. NanoGroup S.A. is currently working on the possibility of extending this time.

Nanogroup - nanotechnology for medicine

– With the research we have conducted so far on our organ storage system, we have scientific confirmation that we are on track to significantly improve organ survival and the ability to continue using organs for transplantation, compared to fluids currently on the market. I am pleased that we can announce the beginning of the next research stage, the expected positive result of which will constitute another important step in bringing our technology to market. Of course, further research to verify the effectiveness of our technology in various simulations is still ahead of us. We see a lot of potential in it and are looking forward to the results of the ongoing research work ,” comments Piotr Mierzejewski, Vice President of the Management Board of NanoGroup S.A..

Copyright © NanoGroup 2023

Prof. Tomasz Ciach

Founder, Member of the Management Board of NANOGROUP S.A.

Nanotechnology expert. Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). Work on various aspects of Biomedical Engineering, mostly on biomedical nanotechnology, active coatings for medical implants, nanoparticles for cancer treatment, biodegradable and nonbiodegradable implants, bone and vascular prosthesis. He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Piotr Mierzejewski

Vice President of the Management Board of NANOGROUP S.A.

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.